Kane Biotech (KNE) Investor Update summary

Key milestones and achievements

• Completed the sale of STEM Animal Health, realizing significant shareholder value and highlighting core technology strengths.

• Scaled up manufacturing and commercial launch of Revive antimicrobial wound gel, with Health Canada approval and ISO 13485 certification.

• FDA increased dosage allowance for Revive gel, enabling the launch of a new spray format, with scale-up manufacturing completed and imminent market introduction.

• Secured NRC-IRAP funding, including a CAD 75,000 grant for multinational collaboration on DispersionB wound gel.

• Signed distribution agreements in the UAE and Qatar, expanding commercial reach.

Strategic initiatives and partnerships

• Acquisition agreement reached for FB Dermatology, expected to provide immediate revenue and expand presence in Australia, New Zealand, and Europe.

• ProGeniCare's acquisition by a larger organization will expand the sales force for Revive from 10 to over 100, accelerating commercialization.

• Distribution strategy leverages partners to minimize costs and maximize product reach, avoiding the need for a large internal salesforce.

2025 objectives and financial outlook

• Key 2025 goals include launching the DispersionB acne clinical trial, closing the FB Dermatology acquisition, and starting the Dispersin wound gel clinical trial.

• Targeting cash flow positivity by end of 2025, with monthly spend maintained at approximately $300,000.

• Expecting significant revenue growth in 2025, with FB Dermatology revenue projected to exceed CAD 2 million.

• Private placement is fully subscribed with oversubscription expected, final closing anticipated in early February.